"Cost-Benefit Analysis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. Cost effectiveness compares alternative ways to achieve a specific set of results.
| Descriptor ID |
D003362
|
| MeSH Number(s) |
N03.219.151.125
|
| Concept/Terms |
Cost-Benefit Analysis- Cost-Benefit Analysis
- Analyses, Cost-Benefit
- Analysis, Cost-Benefit
- Cost-Benefit Analyses
- Cost Benefit Analysis
- Analyses, Cost Benefit
- Analysis, Cost Benefit
- Cost Benefit Analyses
Cost-Utility Analysis- Cost-Utility Analysis
- Analyses, Cost-Utility
- Analysis, Cost-Utility
- Cost Utility Analysis
- Cost-Utility Analyses
Economic Evaluation- Economic Evaluation
- Economic Evaluations
- Evaluation, Economic
- Evaluations, Economic
Marginal Analysis- Marginal Analysis
- Analyses, Marginal
- Analysis, Marginal
- Marginal Analyses
Cost Benefit- Cost Benefit
- Costs and Benefits
- Benefits and Costs
|
Below are MeSH descriptors whose meaning is more general than "Cost-Benefit Analysis".
Below are MeSH descriptors whose meaning is more specific than "Cost-Benefit Analysis".
This graph shows the total number of publications written about "Cost-Benefit Analysis" by people in this website by year, and whether "Cost-Benefit Analysis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 3 | 3 |
| 1998 | 0 | 7 | 7 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 9 | 9 |
| 2001 | 1 | 6 | 7 |
| 2002 | 0 | 6 | 6 |
| 2003 | 0 | 9 | 9 |
| 2004 | 1 | 6 | 7 |
| 2005 | 1 | 9 | 10 |
| 2006 | 0 | 10 | 10 |
| 2007 | 1 | 15 | 16 |
| 2008 | 0 | 11 | 11 |
| 2009 | 0 | 8 | 8 |
| 2010 | 0 | 10 | 10 |
| 2011 | 0 | 10 | 10 |
| 2012 | 0 | 15 | 15 |
| 2013 | 0 | 12 | 12 |
| 2014 | 3 | 14 | 17 |
| 2015 | 5 | 23 | 28 |
| 2016 | 3 | 23 | 26 |
| 2017 | 7 | 21 | 28 |
| 2018 | 5 | 18 | 23 |
| 2019 | 3 | 23 | 26 |
| 2020 | 7 | 22 | 29 |
| 2021 | 2 | 19 | 21 |
| 2022 | 1 | 11 | 12 |
| 2023 | 0 | 13 | 13 |
| 2024 | 7 | 8 | 15 |
| 2025 | 3 | 16 | 19 |
| 2026 | 1 | 6 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cost-Benefit Analysis" by people in Profiles.
-
Surgical Excision Versus Percutaneous Ultrasound-Guided Fenestration for Pediatric Ganglia: A Cost and Recurrence Rate Analysis. J Am Acad Orthop Surg. 2026 Aug 01; 34(15):e2092-e2096.
-
Efficacy, Safety, and Cost-Effectiveness of Reduced versus Full Initial Doses of Androgen Receptor Signaling Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Study. Prostate. 2026 Aug; 86(11):1233-1240.
-
The pro-doc-tivity pause: Health economic benefits of collegial connection. Ann Allergy Asthma Immunol. 2026 07; 137(1):101-106.e7.
-
Cost-Effectiveness of the I'm Ready HIV Self-Testing Programme Among High-Risk Populations in Canada. J Int AIDS Soc. 2026 Apr; 29(4):e70097.
-
A Health-Economic Analysis of Alpha-Gal Screening in the Asymptomatic Patient to Prevent Fatal Anaphylaxis. J Allergy Clin Immunol Pract. 2026 Jul; 14(7):1638-1643.e4.
-
Advancing youth HIV prevention and care in Uganda: stakeholder-informed innovations through implementation science, protocol for a randomized controlled trial. BMC Health Serv Res. 2026 Feb 05; 26(1).
-
Risk-Adapted Combined-Modality Therapy in Early-Stage Extranodal Natural Killer-/T-Cell Lymphoma: A Markov Model-Based Cost-Effectiveness Analysis. JCO Glob Oncol. 2026 Jan; 12:e2400435.
-
Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20?years, in Sub-Saharan Africa. Contemp Clin Trials. 2026 Mar; 162:108213.
-
Cost-effectiveness analysis of surgical repair versus observation of complex abdominal aortic aneurysms in elderly patients. J Vasc Surg. 2026 03; 83(3):699-709.e5.
-
Corrected T1 (cT1) is the most appropriate diagnosis and monitoring tool for widespread adoption of resmetirom treatment in the United States. J Med Econ. 2025 Dec; 28(1):1370-1387.